Want to see ATOS full AI Analyst Report?
ATOS Stock Chart & Stats
$2.64
$0.06(2.40%)
At close: 4:00 PM EDT
$2.64
$0.06(2.40%)
Day’s Range― - ―
52-Week Range$1.70 - $19.33
Previous CloseN/A
Volume20.56K
Average Volume (3M)54.44K
Market Cap
$22.15M
Enterprise Value-$9.01
Total Cash (Recent Filing)$26.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Nov 16, 2026EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.34
Shares Outstanding9,979,298
10 Day Avg. Volume35,891
30 Day Avg. Volume54,441
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.94
Price to Sales (P/S)0.00
P/FCF Ratio-2.56
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$11.00Price Target Upside316.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure reduces refinancing and interest-rate exposure, giving this clinical-stage company greater financial flexibility while it advances its pipeline. It also avoids debt-service demands that could otherwise compete with research spending and clinical development priorities.
EVANGELINE ProgressCompleting Phase 2 enrollment is a meaningful development milestone that moves the lead program closer to generating clinical evidence. Progress in a defined trial can improve the company’s ability to evaluate efficacy, guide later development, and support future strategic partnering discussions.
Broadening PipelineProgress across I-SPY2 collaboration arms and planned Phase 2 programs in additional indications broadens the potential application of the pipeline. Multiple development avenues can create more opportunities for value creation than reliance on a single breast-cancer study.
Bears Say
No Commercial RevenueThe absence of commercial revenue means ATOS has not yet demonstrated a recurring product-based funding engine. Its ability to support research and clinical programs therefore remains dependent on available capital and successful development progress rather than internally generated sales.
Widening Net LossesWorsening net losses indicate that the company remains far from self-sustaining and that development spending is not yet translating into operating leverage. If this trajectory persists, more capital may be required before the pipeline can produce commercial or partnering income.
Increasing Cash BurnRising operating cash burn increases funding pressure even without debt, because ongoing trials and research require substantial cash outlays. A higher burn rate can shorten the period covered by existing resources and raise the likelihood of future equity financing and dilution.
Atossa Therapeutics News
ATOS FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was $1.70 and its highest was $19.33 in the past 12 months.
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is $22.15M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 56 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on Aug 07, 2026. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.025 by $0.075.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -0.9.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 9,979,298 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.025. Following the earnings report the stock price went down -2.479%.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in ATOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
ATOS Stock 12 Month Forecast
Average Price Target
$11.00
▲(316.67% Upside)
Technical Analysis
Ownership Overview
2.17% Insiders
27.42% Mutual Funds
1.46% Other Institutional Investors
65.08% Public Companies and
Individual Investors